International Recognition Procedure

AI Summary

The Medicines and Healthcare products Regulatory Agency (MHRA) has introduced the International Recognition Procedure (IRP), which officially became effective on January 1, 2024. This regulatory framework is designed to provide patients in the United Kingdom with expedited access to safe and effective medicines by leveraging existing approvals from trusted global partners. These partners include regulatory bodies from Australia, Canada, the European Union, Japan, Switzerland, Singapore, and the United States. This new route operates in conjunction with the MHRA’s existing national procedures to streamline the approval process. While the document does not list specific company violations or inspection dates, it details the necessary actions for applicants seeking to use this pathway. Organizations must complete a mandatory eligibility checker form and are advised to thoroughly review the MHRA's guidance and pre-application questions. Additionally, applicants should coordinate with their IT departments to ensure they can save documentation in the required PDF format. To facilitate a smooth transition, the MHRA provided educational webinars in November 2023 and April 2024, which offer detailed instructions and post-launch updates for prospective applicants to follow.